AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9542820 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored serum cholesterol concentration
Number of subjects: 686
Study 9542820 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored serum triglyceride concentration
Number of subjects: 686
Study 9542820 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of diabetes mellitus during follow-up
Number of subjects: 686
Study 7980331 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% BAC)
Number of subjects: 28
Study 7980331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2577394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) administration of 30 mg/l vancomycin for 10 days
Number of subjects: 40
Study 2577394 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 1 gram of vancomycin (2 infusions: first on diagnosis day, second 7 days later)
Number of subjects: 40
Study 806789 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.10 mg reserpine, 10 mg mefruside, and 125 mg alpha-methyldopa
Number of subjects: 30
Study 806789 — intervention group
Group type: COMPARATOR
Intervention: Combination of 0.15 mg reserpine, 15 mg mefruside, and 150 mg inositol nicotinate
Number of subjects: 30
Study 31522082 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning catechin-rich green tea trial (MGT)
Number of subjects: 17
Study 31522082 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening catechin-rich green tea trial (EGT)
Number of subjects: 17
Study 31522082 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning and evening catechin-rich green tea trials
Number of subjects: 17
Study 28664349 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline/Malate (stimol) 3 times a day as 1 g for breakfast, 1 g for lunch, and 1 g for dinner
Number of subjects: 22
Study 28664349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dosage and timing as stimol)
Number of subjects: 22
Study 28664349 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline/Malate (stimol)
Number of subjects: 22
Study 26177810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once a day for thromboprophylaxis
Number of subjects: 766
Study 26177810 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of deep and superficial blocks
Number of subjects: 766
Study 23169243 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT in combination with a feces collection paper (n=5129)
Number of subjects: 10265
Study 23169243 — intervention group
Group type: COMPARATOR
Intervention: FIT-only group (n=5136)
Number of subjects: 10265
Study 20482446 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC(3%LUV)
Number of subjects: 30
Study 20482446 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC(2%LUV)
Number of subjects: 30
Study 20482446 — intervention group
Group type: COMPARATOR
Intervention: MVC(2%EPI)
Number of subjects: 30
Study 18305080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal opioid (LITO): morphine 5 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Number of subjects: 46
Study 18305080 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intrathecal opioid (HITO): morphine 15 microg kg(‐1) plus sufentanil 1 microg kg(‐1)
Number of subjects: 46
Study 18305080 — intervention group
Group type: COMPARATOR
Intervention: Control group: no intrathecal opioid
Number of subjects: 46
Study 16421677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.0 mg.kg(‐1) (group L1)
Number of subjects: 80
Study 16421677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg(‐1) (group L2)
Number of subjects: 80
Study 16421677 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 80
Study 12953851 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide)
Number of subjects: 6105
Study 12953851 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril and indapamide) with recurrent stroke
Number of subjects: 6105
Study 10730037 — intervention group
Group type: EXPERIMENTAL
Intervention: Xmn I polymorphic site presence (7.0 kb fragment)
Number of subjects: 30
Study 10730037 — intervention group
Group type: EXPERIMENTAL
Intervention: Xmn I polymorphic site absence (8.1 kb fragment)
Number of subjects: 30
Study 10730037 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Saudi Arabs
Number of subjects: 30
Study 8885344 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging
Number of subjects: 60
Study 8885344 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional imaging
Number of subjects: 60
Study 1528712 — intervention group
Group type: EXPERIMENTAL
Intervention: Recormon
Number of subjects: 30
Study 1528712 — intervention group
Group type: COMPARATOR
Intervention: Eprex
Number of subjects: 30
Study 4008686 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (gelatin capsules containing microcrystalline 8‐MOP with particle size between 20 mu and 30 mu)
Number of subjects: 30
Study 4008686 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C (microcrystalline 8‐MOP in an emulsion base)
Number of subjects: 30
Study 4008686 — intervention group
Group type: COMPARATOR
Intervention: Formulation A (gelatin capsules containing 8‐MOP with a mean particle size of 200 mu)
Number of subjects: 30
Study 30768662 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent transmucosal morphology
Number of subjects: 21
Study 30768662 — intervention group
Group type: COMPARATOR
Intervention: Divergent transmucosal morphology
Number of subjects: 21
Study 30208456 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis during 2 chemotherapy cycles for acute leukemia (n=100)
Number of subjects: 624
Study 30208456 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis during 1 HSCT procedure (n=210)
Number of subjects: 624
Study 30208456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis) for acute leukemia (n=100)
Number of subjects: 624
Study 30208456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis) for HSCT (n=214)
Number of subjects: 624
Study 30208456 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis
Number of subjects: 624
Study 27007919 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (300mg/d for 12 weeks)
Number of subjects: 0
Study 25295716 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/GSD patch
Number of subjects: 100
Study 25295716 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/NGMN patch
Number of subjects: 100
Study 22198974 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol, 400 mg twice a day
Number of subjects: 318
Study 22198974 — intervention group
Group type: COMPARATOR
Intervention: Inhaled mannitol, 50 mg twice a day (control)
Number of subjects: 318
Study 20166158 — intervention group
Group type: EXPERIMENTAL
Intervention: Paring followed by IPL
Number of subjects: 89
Study 20166158 — intervention group
Group type: COMPARATOR
Intervention: Paring alone
Number of subjects: 89
Study 16971160 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy dynamometer (100N force)
Number of subjects: 30
Study 16971160 — intervention group
Group type: COMPARATOR
Intervention: Therapists' own estimate of a grade III mobilization force using hands
Number of subjects: 30
Study 15166856 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 0
Study 11350770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training alone
Number of subjects: 16
Study 11350770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training combined with rhGH administration
Number of subjects: 16
Study 11350770 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 16
Study 11350770 — intervention group
Group type: COMPARATOR
Intervention: GH group (control)
Number of subjects: 16
Study 9305340 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo E epsilon 4 allele presence
Number of subjects: 538
Study 8198264 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol (Group A)
Number of subjects: 71
Study 8198264 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg butorphanol (Group B)
Number of subjects: 71
Study 8198264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg butorphanol (Group C)
Number of subjects: 71
Study 8198264 — intervention group
Group type: COMPARATOR
Intervention: 3 mL normal saline (Group D)
Number of subjects: 71
Study 2967256 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine (sympathetic block)
Number of subjects: 0
Study 2967256 — intervention group
Group type: COMPARATOR
Intervention: Control (non-blocked arms)
Number of subjects: 0
Study 29696917 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint catgut embedding sequential therapy
Number of subjects: 120
Study 29696917 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine
Number of subjects: 120
Study 27716064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Amiloride
Number of subjects: 4396
Study 27716064 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4396
Study 27716064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4396
Study 25694461 — intervention group
Group type: EXPERIMENTAL
Intervention: 80+ score
Number of subjects: 368
Study 25694461 — intervention group
Group type: COMPARATOR
Intervention: STOPP
Number of subjects: 368
Study 25694461 — intervention group
Group type: COMPARATOR
Intervention: START
Number of subjects: 368
Study 25694461 — intervention group
Group type: COMPARATOR
Intervention: MAI
Number of subjects: 368
Study 23678828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid treatment for four months
Number of subjects: 20
Study 20684711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU)
Number of subjects: 287
Study 20684711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 19008684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping neck support (n=76)
Number of subjects: 149
Study 19008684 — intervention group
Group type: COMPARATOR
Intervention: Control group without sleeping neck support (n=73)
Number of subjects: 149
Study 16800100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine/lamivudine/stavudine combination tablet (200 mg/150 mg/30 mg)
Number of subjects: 40
Study 16800100 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine 200 mg, Lamivudine 150 mg, and Stavudine 30 mg administered concurrently as separate formulations
Number of subjects: 40
Study 12903886 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln-enriched enteral nutrition (0.35 g gln/kg body weight/d)
Number of subjects: 40
Study 12903886 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formulation
Number of subjects: 40
Study 12903886 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln-enriched enteral nutrition
Number of subjects: 40
Study 11191542 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody to IL-5 (SB-240563) at 10 mg/kg
Number of subjects: 16
Study 11191542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11191542 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody to IL-5 (SB-240563)
Number of subjects: 16
Study 9167750 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intravenously
Number of subjects: 15
Study 9167750 — intervention group
Group type: COMPARATOR
Intervention: Brain irradiation (20 Gy)
Number of subjects: 15
Study 1494972 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation techniques
Number of subjects: 33
Study 1494972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback-assisted relaxation)
Number of subjects: 33
Study 6418374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimethoprim-sulfamethoxazole plus erythromycin (TMZ-E)
Number of subjects: 57
Study 6418374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 57
Study 31044227 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure variability (BPV)
Number of subjects: 111
Study 31044227 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BPV
Number of subjects: 111
Study 31044227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean diastolic blood pressure
Number of subjects: 111
Study 31044227 — intervention group
Group type: EXPERIMENTAL
Intervention: High home BPV
Number of subjects: 111
Study 30180755 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV + LGSIL
Number of subjects: 75
Study 30180755 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV + HGSIL
Number of subjects: 75
Study 30180755 — intervention group
Group type: COMPARATOR
Intervention: Control (HPV-negative healthy women)
Number of subjects: 75
Study 27317704 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan treatment
Number of subjects: 240
Study 25137243 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 7.5 mg
Number of subjects: 1184
Study 25137243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1184
Study 22040465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil- and micronutrient-enriched formula
Number of subjects: 40
Study 22040465 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic formula (Control)
Number of subjects: 40
Study 20055785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroimidazole antibiotics (metronidazole, ornidazole)
Number of subjects: 7
Study 20055785 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 7
Study 20055785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 18522729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined written and oral information (N = 278)
Number of subjects: 577
Study 18522729 — intervention group
Group type: COMPARATOR
Intervention: Oral information alone (N = 299)
Number of subjects: 577
Study 18522729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined written and oral information
Number of subjects: 577
Study 16045524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 30
Study 11815506 — intervention group
Group type: COMPARATOR
Intervention: HemoCue B‐Glucose Analyzer
Number of subjects: 50
Study 11815506 — intervention group
Group type: COMPARATOR
Intervention: Sof‐Tact Blood Glucose System
Number of subjects: 50
Study 11815506 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue B‐Hemoglobin Photometer
Number of subjects: 50
Study 10398914 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 80
Study 10398914 — intervention group
Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 80
Study 7668657 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarion system
Number of subjects: 0
Study 7668657 — intervention group
Group type: COMPARATOR
Intervention: Nucleus system
Number of subjects: 0
Study 2039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 100 mg
Number of subjects: 0
Study 2039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 200 mg
Number of subjects: 0
Study 2039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 400 mg
Number of subjects: 0
Study 2039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg
Number of subjects: 0
Study 2039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 800 mg
Number of subjects: 0
Study 2039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 1000 mg
Number of subjects: 0
Study 2039194 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin (all doses)
Number of subjects: 0
Study 6861436 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone doses (0, 1, 5, 10, 25, or 50 mg)
Number of subjects: 7
Study 6861436 — intervention group
Group type: EXPERIMENTAL
Intervention: $1 alternative
Number of subjects: 7
Study 6861436 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinalysis results indicating recent illicit opiate use
Number of subjects: 7
Study 6861436 — intervention group
Group type: COMPARATOR
Intervention: Subjective withdrawal symptoms
Number of subjects: 7
Study 30339481 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression sleeves (15 mmHg) worn for 2 years
Number of subjects: 41
Study 30339481 — intervention group
Group type: COMPARATOR
Intervention: Control group without compression
Number of subjects: 41
Study 30285632 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of OSAS patients
Number of subjects: 43
Study 30285632 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 27535327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention by practice nurse-GP team
Number of subjects: 287
Study 27535327 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 287
Study 25014686 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin and 40 mg of laropiprant
Number of subjects: 25673
Study 25014686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25673
Study 23025568 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused 'Active Play' intervention (10-week program delivered by trained professionals)
Number of subjects: 77
Study 23025568 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (maintained usual routine)
Number of subjects: 77
Study 20196846 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (penicillin V)
Number of subjects: 123
Study 20196846 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 123
Study 18073338 — intervention group
Group type: EXPERIMENTAL
Intervention: Work, Weight, and Wellness program (intervention)
Number of subjects: 11559
Study 16722024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (SH)
Number of subjects: 30
Study 16722024 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide (AH)
Number of subjects: 30
Study 15373932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg, twice daily for 5 days)
Number of subjects: 10
Study 15373932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10908773 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 100 mg vaginal ovules (intravaginally for 3 days) plus placebo capsules (orally twice daily for 7 days)
Number of subjects: 399
Study 10908773 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg (two 250 mg capsules orally twice daily for 7 days) plus placebo ovules (intravaginally for 3 days)
Number of subjects: 399
Study 10908773 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole treatment group
Number of subjects: 399
Study 8717802 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation programme (CRP) for six months
Number of subjects: 0
Study 1424831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside examination
Number of subjects: 103
Study 1424831 — intervention group
Group type: COMPARATOR
Intervention: Videofluoroscopy
Number of subjects: 103
Study 3901562 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil retard preparation 240 mg b.i.d.
Number of subjects: 54
Study 3901562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard preparation 20 mg b.i.d.
Number of subjects: 54
Study 3901562 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 54
Study 31164040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 74
Study 31164040 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity recommendation from the World Health Organization group (PAR)
Number of subjects: 74
Study 31164040 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training group (HIIT)
Number of subjects: 74
Study 31164040 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training group adding whole-body electromyostimulation training group (HIIT-EMS)
Number of subjects: 74
Study 28528340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric high‐protein diet (1.2‐1.4 g / kg body weight reference / day)
Number of subjects: 18
Study 28528340 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet plus placebo
Number of subjects: 18
Study 26169611 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily (E + T)
Number of subjects: 1048
Study 26169611 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib plus placebo (E + P)
Number of subjects: 1048
Study 24279686 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT followed by FALLS (intervention)
Number of subjects: 497
Study 24279686 — intervention group
Group type: COMPARATOR
Intervention: FALLS alone (control)
Number of subjects: 497
Study 21561900 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1305 (50 mg/h)
Number of subjects: 171
Study 21561900 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1305 (100 mg/h)
Number of subjects: 171
Study 21561900 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1305 (130 mg/h)
Number of subjects: 171
Study 21561900 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1305 (180 mg/h)
Number of subjects: 171
Study 21561900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 18253819 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception condition
Number of subjects: 1300
Study 18253819 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Memory condition
Number of subjects: 1300
Study 18253819 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Memory condition
Number of subjects: 1300
Study 18253819 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐m viewing distance
Number of subjects: 1300
Study 16390894 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (high-frequency left-side and low-frequency right-side)
Number of subjects: 50
Study 16390894 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study 14667875 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH 150 IU for 3 months
Number of subjects: 33
Study 14667875 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 33